The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
Open accessAbstract
To guide vaccine design, we assessed whether human monoclonal antibodies (MAbs) b12 and b6 against the CD4 binding site (CD4bs) on HIV-1 gp120 and F240 against an immundominant epitope on gp41 could prevent vaginal transmission of simian HIV (SHIV)-162P4 to macaques. The two anti-gp120 MAbs have similar monomeric gp120-binding properties, measured in vitro, but b12 is strongly neutralizing and b6 is not. F240 is nonneutralizing. Applied vaginally at a high dose, the strongly neutralizing MAb b12 provided sterilizing immunity in seven of seven animals, b6 in zero of five animals, and F240 in two of five animals. Compared with control animals, the protection by b12 achieved statistical significance, whereas that caused by F240 did not. For two of three unprotected F240-treated animals there was a trend toward lowered viremia. The potential protective effect of F240 may relate to the relatively strong ability of this antibody to capture infectious virions. Additional passive transfer experiments also indicated that the ability of the administered anti-gp120 MAbs to neutralize the challenge virus was a critical influence on protection. Furthermore, when data from all of the experiments were combined, there was a significant increase in the number of founder viruses establishing infection in animals receiving MAb b6, compared with other nonprotected macaques. Thus, a gp120-binding, weakly neutralizing MAb to the CD4bs was, at best, completely ineffective at protection. A nonneutralizing antibody to gp41 may have a limited capacity to protect, but the results suggest that the central focus of HIV-1 vaccine research should be on the induction of potently neutralizing antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody
Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W. H. I., Sawyer, L. S. W., Hendry, R. M., Dunlop, N., Nara, P. L., et al. (1994) · Science · doi:10.1126/science.7973652 · Cited by 1,100
Self-citationFc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Self-citationMascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.4009-4018.1999 · Cited by 783
Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13232-13252.2004 · Cited by 705
Self-citationParren, P. W. H. I., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P., & Burton, D. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.17.8340-8347.2001 · Cited by 662
Self-citationHessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., Parren, P. W. H. I., Marx, P. A., & Burton, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1974 · Cited by 546
Self-citationShibata, R., Igarashi, T., Haigwood, N., Buckler–White, A., Ogert, R., Ross, W., Willey, R., Cho, M. W., & Martin, M. A. (1999) · Nature Medicine · doi:10.1038/5568 · Cited by 539
Progesterone implants enhance SIV vaginal transmission and early virus load
Marx, P. A., Spira, A. I., Gettie, A., Dailey, P. J., Veazey, R. S., Lackner, A. A., Mahoney, C. J., Miller, C. J., Claypool, L. E., Ho, D. D., et al. (1996) · Nature Medicine · doi:10.1038/nm1096-1084 · Cited by 465
Self-citationVeazey, R. S., Shattock, R. J., Pope, M., Kirijan, J. C., Jones, J., Hu, Q., Ketas, T., Marx, P. A., Klasse, P. J., Burton, D. R., et al. (2003) · Nature Medicine · doi:10.1038/nm833 · Cited by 460
Self-citationHIV/AIDS in Women: An Expanding Epidemic
Quinn, T. C., & Overbaugh, J. (2005) · Science · doi:10.1126/science.1112489 · Cited by 417 · cited 1×
“In the absence of progesterone, infection of macaques is more likely to occur in the luteal phase of the menstrual cycle, when the vaginal epithelium is at its thinnest, and it is possible that similar, natural variations in the risk of HIV-1 infection also arise in women (30).”
BackgroundThe Role of Antibodies in HIV Vaccines
Mascola, J. R., & Montefiori, D. C. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101256 · Cited by 388
Distinct Pathogenic Sequela in Rhesus Macaques Infected with CCR5 or CXCR4 Utilizing SHIVs
Harouse, J. M., Gettie, A., Tan, R. C. H., Blanchard, J., & Cheng-Mayer, C. (1999) · Science · doi:10.1126/science.284.5415.816 · Cited by 320
Keele, B. F., Li, H., Learn, G. H., Hraber, P., Giorgi, E. E., Grayson, T., Sun, C., Chen, Y., Yeh, W. W., Letvin, N. L., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082831 · Cited by 311
Self-citationBomsel, M., Tudor, D., Drillet, A.-S., Alfsen, A., Ganor, Y., Roger, M.-G., Mouz, N., Amacker, M., Chalifour, A., Diomede, L., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.015 · Cited by 293
The antiviral activity of antibodies in vitro and in vivo
Parren, P. W. H. I., & Burton, D. R. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)77018-6 · Cited by 261
Self-citationPantophlet, R., Saphire, E. O., Poignard, P., Parren, P. W. H. I., Wilson, I. A., & Burton, D. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.642-658.2003 · Cited by 244
Self-citationRational antibody-based HIV-1 vaccine design: current approaches and future directions
Walker, L. M., & Burton, D. R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.012 · Cited by 210
Self-citationParren, P. W. H. I., Mondor, I., Naniche, D., Ditzel, H. J., Klasse, P. J., Burton, D. R., & Sattentau, Q. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.3512-3519.1998 · Cited by 189
Self-citationPoignard, P., Moulard, M., Golez, E., Vivona, V., Franti, M., Venturini, S., Wang, M., Parren, P. W. H. I., & Burton, D. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.353-365.2003 · Cited by 188
Self-citationZwick, M. B., Wang, M., Poignard, P., Stiegler, G., Katinger, H., Burton, D. R., & Parren, P. W. H. I. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12198-12208.2001 · Cited by 160
Self-citationVeazey, R. S., Ketas, T. J., Dufour, J., Moroney‐Rasmussen, T., Green, L. C., Klasse, P. J., & Moore, J. P. (2010) · The Journal of Infectious Diseases · doi:10.1086/655661 · Cited by 132
Self-citationSullivan, N. J., Sun, Y., Binley, J. Μ., Lee, J., Barbas, C. F., Parren, P. W. H. I., Burton, D. R., & Sodroski, J. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6332-6338.1998 · Cited by 130
Self-citationHIV vaccines: lessons learned and the way forward
Kim, J. H., Rerks‐Ngarm, S., Excler, J., & Michael, N. L. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833d17ac · Cited by 130
HIV-1 Vaccine Development After STEP
Barouch, D. H., & Korber, B. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.042508.093728 · Cited by 119
Liu, J., Keele, B. F., Li, H. J., Keating, S. M., Norris, P. J., Carville, A., Mansfield, K. G., Tomaras, G. D., Haynes, B. F., Kolodkin‐Gal, D., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01155-10 · Cited by 115
Self-citationMascola, J. R., Louder, M. K., Winter, C., Prabhakara, R., Rosa, S. C. D., Douek, D. C., Hill, B. J., Gabuzda, D. H., & Roederer, M. (2002) · Journal of Virology · doi:10.1128/jvi.76.10.4810-4821.2002 · Cited by 108
Klasse, P. J. (2007) · Virology · doi:10.1016/j.virol.2007.06.044 · Cited by 103
Self-citationStone, M., Keele, B. F., Ma, Z.-M., Bailes, E., Dutra, J., Hahn, B. H., Shaw, G. M., & Miller, C. J. (2010) · Journal of Virology · doi:10.1128/jvi.00481-10 · Cited by 96
Self-citationCavacini, L. A., Emes, C. L., Wisnewski, A. V., Power, J., LEWIS, G., Montefiori, D. C., & Posner, M. R. (1998) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1998.14.1271 · Cited by 77
Self-citationA Boost for HIV Vaccine Design
Burton, D. R., & Weiss, R. A. (2010) · Science · doi:10.1126/science.1194693 · Cited by 69
Self-citationTransmission of Single and Multiple Viral Variants in Primary HIV-1 Subtype C Infection
Novitsky, V., Wang, R., Margolin, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016714 · Cited by 46
Willey, R. L., Nason, M., Nishimura, Y., Follmann, D. A., & Martin, M. A. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2009.0144 · Cited by 41
Cavacini, L. A., Duval, M., Robinson, J. E., & Posner, M. R. (2002) · AIDS · doi:10.1097/00002030-200212060-00005 · Cited by 37
Self-citationHIV vaccines: mosaic approach to virus diversity
Corey, L., & McElrath, M. J. (2010) · Nature Medicine · doi:10.1038/nm0310-268 · Cited by 34
Strategies for eliciting HIV-1 inhibitory antibodies
Tomaras, G. D., & Haynes, B. F. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833d2d45 · Cited by 34
Miranda, L. R., Duval, M., Doherty, H., Seaman, M. S., Posner, M. R., & Cavacini, L. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7132 · Cited by 32
Self-citation
Cited by
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Lynch, R. M., Boritz, E., Coates, E. E., DeZure, A., Madden, P., Costner, P., Enama, M. E., Plummer, S., Holman, L., Hendel, C. S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5752 · Cited by 465
Moldt, B., Rakasz, E. G., Schultz, N., Chan-Hui, P.-Y., Swiderek, K., Weisgrau, K. L., Piaskowski, S. M., Bergman, Z., Watkins, D. I., Poignard, P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214785109 · Cited by 463
Self-citationAntibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
Antibody responses to envelope glycoproteins in HIV-1 infection
Burton, D. R., & Mascola, J. R. (2015) · Nature Immunology · doi:10.1038/ni.3158 · Cited by 385
Self-citation
Metadata
- Authors
- Burton, D. R., Hessell, A. J., Keele, B. F., Klasse, P. J., Ketas, T. A., Moldt, B., Dunlop, D. C., Poignard, P., Doyle, L. A., Cavacini, L., Veazey, R. S., & Moore, J. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-06-20
- Volume
- 108
- Issue
- 27
- Pages
- 11181-11186
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2063789804
- Cited by
- 255
- References
- 37
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.